Drugs / PCI-27483
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01020006 | Nov 2009 → Aug 2012 | adenocarcinoma, exocrine pancreatic carcinoma | Pharmacyclics LLC. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCI-27483 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01020006 ↗ |
| Known as | Cra-027483 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297315 ↗ |
| Known as | PCYC-1001, PCI-27483 Injection | “PCYC-1001, PCI-27483 Injection” NCT01020006 ↗ |
| Action | Inhibit | “Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine” NCT01020006 ↗1“Coagulation factor VII inhibitor” CHEMBL4297315 ↗ |
| Modality | Small molecule | — CHEMBL4297315 ↗ |
| Route | Subcutaneous | “PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID.” NCT01020006 ↗ |
| Target | F7 | “Coagulation factor VII inhibitor” CHEMBL4297315 ↗ |